A new dietary silicon-based antioxidant agent prevented neurodegeneration, and motor balance and coordination problems, in a mouse model of Parkinson’s disease. By promoting production of the antioxidant molecule hydrogen, the agent  also was shown to prevent kidney failure in a rat model of chronic kidney disease, another…
Sedentary behavior during waking hours is linked to poorer attention spans in people with mild to moderate Parkinson’s disease, a small pilot study in patients reports. The study, “Sedentary Time is Associated with Worse Attention in Parkinson’s Disease: A Pilot Study,” was published in the Journal…
Older men who have a weak or irregular circadian rhythm — the body’s internal clock that controls the sleep-wake cycle — are approximately three-times more likely to develop Parkinson’s disease later in life, compared to those who have regular activity-rest cycles, a study has found. According to researchers,…
An infusion of levodopa/carbidopa to the intestines may be a therapeutic option for Parkinson’s disease patients who develop freezing of gait following deep brain stimulation, according to a recent study. The study, “Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Unresponsive Freezing of Gait after…
New magnetic resonance imaging (MRI) techniques capable of zeroing in on a pea-size region of the brain responsible for movement control may allow physicians to treat patients with Parkinson’s disease or essential tremor without having to resort to invasive brain surgery. These methods were described in the…
Coenzyme Q10, an antioxidant supplement that, when taken orally, has shown limited effectiveness, can alleviate Parkinson’s disease symptoms when injected directly into the brain, a study in rats suggests. The study, “Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson’s disease rat model,”…
Erisyon, a biotechnology company specializing in the study of proteins, was awarded a grant by The Michael J. Fox Foundation (MJFF) to find and validate potential markers of Parkinson’s disease in its early stages. The grant, reported to be worth $189,000, will go toward deploying single-molecule protein sequencing to detect and…
Parkinson Canada is inviting patients to join the Canadian Open Parkinson Network (C-OPN) to help advance Parkinson’s disease care and research. The national research platform seeks to drive more efficient research, accelerate disease understanding, and uncover new treatments for the neurodegenerative disorder. The hope is to facilitate rapid…
Structural changes within alpha-synuclein can make this protein more prone to clumping — a common feature of Parkinson’s — a research group found, a discovery that might lead to ways of stopping this disease in its early stages. The study, “Extent of N-terminus exposure of monomeric alpha-synuclein…
Kynmobi (apomorphine hydrochloride) soluble film has been approved by Health Canada as an on-demand treatment for off episodes in people with Parkinson’s disease, its developer Sunovion, announced. Sunovion…
Get regular updates to your inbox.
